Background: Little is known on the risk of cancer in HIV-positive children
INTRODUCTION
South Africa is one of the countries most heavily affected by the HIV epidemic. An estimated 6.3 million people were living with HIV in South Africa in 2013, including 360,000 children. 1 HIV-positive children are at higher risk of developing cancer than children from the general population [2] [3] [4] or HIV-negative children. [5] [6] [7] [8] Studies from Europe and the United States of America (USA) have shown that the incidence of cancer has declined as combination antiretroviral therapy (ART) has become more widely available. 3, 4, 9 Cohort studies of HIV-positive children are rare in the African region, and no study has so far assessed the impact of ART on the risk of developing cancer. 10 Moreover, data collection is often restricted to AIDSdefining cancers, i.e. Kaposi sarcoma (KS) and non-Hodgkin Lymphoma (NHL) in these cohorts. 11 Even the data on AIDS-defining cancers may be incomplete, since cohorts are based in ART programs but cancers are treated in pediatric oncology units. Record linkages with cancer registries can overcome these limitations but to date only one record linkage study from the pre-ART era reported the incidence rate of cancer in HIV-positive children in an African setting. 12 Lastly, it may be difficult to estimate incidence and risk factors with precision because the number of HIVpositive children followed-up in any single cohort is typically small.
We did a record linkage study that combined data from five HIV cohort studies that participate in the International epidemiologic Databases to Evaluate AIDS (IeDEA) with the records of the four referral pediatric oncology units in South Africa. We aimed to define the incidence rate, risk factors and the impact of ART on the development of AIDS-defining and 
MATERIALS AND METHODS

Data sources
IeDEA is a research consortium established in 2006 to inform the scale-up of ART through clinical and epidemiological research. were defined as cancers diagnosed before or at enrolment into the cohort.
Incident cases were defined as cancers diagnosed during follow-up.
Statistical methods
In children not on ART, we measured time from the date of enrolment to the earliest of the date of diagnosis, start of ART, last follow-up visit or death. In children on ART, we measured time from the start of ART to the earliest of the date of the cancer diagnosis, last follow-up visit, or death. In children who were ART naïve at enrolment and who started ART during follow-up, we split the follow-up time so that they contributed time both to the not-on-ART and the on-ART analysis. We took an intent-to-continuetreatment approach and ignored changes to ART regimens, including interruptions and terminations. Incidence rates were calculated by dividing the number of children who developed cancer by the number of person-years at risk, with Poisson 95% confidence intervals (CI). We examined risk factors for incident cancer in Cox proportional hazard models stratified by cohort. Multivariable models were adjusted for time-updated ART, age at enrolment, sex, and degree of immunodeficiency (none, mild, advanced, severe) at enrolment. Missing CD4 counts and CD4% were multiply imputed using predictive mean matching and chained equations stratified by
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gender and age. In sensitivity analyses we restricted the analysis to the complete data and excluded patients with missing data.
Results are presented as medians with interquartile ranges (IQR), incidence rates per 100,000 person-years, Kaplan-Meier estimates of the cumulative incidence and crude and adjusted hazard ratios (HRs), with 95%
CI. Stata version 13 (Stata Corporation, College Station, Texas, USA) was used for all statistical analyses.
RESULTS
The five ART cohorts included 12,448 eligible children ( cell measurements at enrolment were available for 7,995 (64%) children. Of these children, 5,333 (67%) presented with advanced or severe immunodeficiency ( Table 1) . The median CD4 cell count at enrolment was 493 cells/µL (IQR 216-922), the median CD4% was 15% (IQR 9%-23%).
Among children with missing CD4 cell measurements, the imputed median CD4 cell count was 664 cells/µL (IQR 396-906) and the imputed median CD4% was 16% (IQR 13%-19%) at enrolment.
We identified a total of 71 eligible children with cancer: 49 (69%)
were identified in the records of the oncology departments, 11 children (15%) were recorded with cancer in the ART programs, and 11 children 
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presented with cancer or developed cancer later on were older at enrolment than children free of cancer: the median age at enrolment was 6.6 years and 5.0 years in children with prevalent and incident cancer, respectively, and 2.5 years in children not developing cancer. Children who developed cancer during follow-up were more likely to have experienced advanced or severe immunodeficiency than children who did not develop cancer (Table 1) . Table 2 
Cancer incidence and risk factors for developing cancer
The analyses of incidence were based on 11,707 children, of whom 24 
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follow-up. In children on ART, the cancer incidence rate was 50/100,000
person-years (95% CI 29-89); in children not on ART, the rate was 220/100,000 person-years (95% CI 125-387) ( Table 3 ). The incidence of AIDS-defining cancers was 65/100,000, with an incidence rate of 34/100,000 for KS, and 31/100,000 for NHL. The incidence of non AIDSdefining cancers was 17/100,000 person-years. The rate of cancer typically associated with EBV infection (NHL, Hodgkin lymphoma, leiomyosarcoma) was 34/100,000 person-years. 
DISCUSSION
This study shows that HIV-positive children in South Africa were at high risk of developing cancer with an overall incidence rate of 82/100,000
person-years. The majority of cancers were AIDS-defining with an incidence rate of 34/100,000 person-years for KS and 31/100,000 personyears for NHL. There were few non AIDS-defining malignancies with an incidence rate of 17/100,000 person-years. Children on ART had a substantially lower risk of developing cancer than children not on ART in multivariable analyses based on imputing data (HR 0.29, 95% CI 0.09-0.86).
In complete case analysis the effect of ART was similar but not statistically significant. In all analyses the risk of developing cancer increased with age at enrolment. This is the first study to describe the incidence rate of AIDS-defining and non AIDS-defining cancer and to estimate the impact of ART on the risk of developing cancer in HIV-positive children in South Africa. We used record linkage to identify both AIDS-defining and non AIDS-defining cancer cases, which are often not recorded, or only incompletely recorded in the data of HIV care and treatment programs. However, we may have missed cancer cases in children who were lost to follow-up or who sought treatment in other clinics. We identified only 24 incident cancer cases, and this limited our ability to conduct analyses stratified for different cancer types. Measurements of CD4 cell counts and percentages, HIV RNA loads, weight and height at enrolment into cohort were missing for a substantial proportion of patients. To overcome this limitation we used multiple imputation methods to impute missing CD4 cell measurements. This is a relatively young cohort (median age 2.5 years) most likely due to inclusion Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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of many secondary and tertiary care sites where younger children and infants tend to be started on treatment. Given that we showed a strong association between older age and incident malignancy, the burden of malignancy may be higher in cohorts of older children. Median time between enrolment and cancer diagnosis was short and we cannot exclude that some of the cancers classified as incident cancer were actually prevalent cancers which had not been diagnosed before enrolment.
Our study showed a cancer incidence rate of 69/100,000 person-years in HIV-positive children in the ART era (2005 or later), which is substantially higher than the Globocan 2012 cancer incidence rates in children aged < 14 years in South Africa (5/100,000 person-years), Europe (13/100,000 person-years), and the US (16/100,000 person-years). 22 Our incidence rates are lower than estimates from previous studies done in HIVpositive children in Europe and the US, see Table 5 . 3, 4, 9 It is difficult to directly compare studies because of different study designs, settings and populations. The US AIDS cancer match study 2, 4 only included children diagnosed with AIDS, while the Italian HIV Registry 9, 23 and our study also included children with HIV that had not yet progressed to AIDS. The Italian HIV Registry study was predominantly based on children aged under one year 9 whereas the median age at enrolment was 2.5 years in our study and Table 5 . Also, the risk of developing cancer tended to increase if immunodeficiency was more advanced at the time the child was enrolled into the cohort. This is in line with previous studies that showed that advanced stage HIV/AIDS disease, 3, 9 or CD4 cell percentages below 15%
(severely immunosuppressed), increased the risk of developing cancer. 
